These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3898374)

  • 1. Development of heparin fractions: some overlooked considerations.
    Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):227-36. PubMed ID: 3898374
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin fractions and derivatives.
    Wehrmacher WH
    Semin Thromb Hemost; 1985 Apr; 11(2):218-21. PubMed ID: 3898372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 7. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin.
    Mardiguian J; Trillou M
    Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of intrapulmonary heparin.
    Bick RL; Ross ES
    Semin Thromb Hemost; 1985 Apr; 11(2):213-7. PubMed ID: 3898371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present state of heparin therapy].
    Blatrix C; Soulier JP; Vacheron A; Cornu P
    Presse Med (1893); 1969 Mar; 77(15):553-6. PubMed ID: 5796027
    [No Abstract]   [Full Text] [Related]  

  • 16. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin therapy.
    Raich PC; Hahn MF; Korst DR
    Am Fam Physician; 1974 Sep; 10(3):163-8. PubMed ID: 4413661
    [No Abstract]   [Full Text] [Related]  

  • 19. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
    Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
    Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.